Centessa Pharmaceuticals plc (CNTA) ADS EACH REPR 1 ORD SHS
1.95%- This stock can be held in a
Create an alert
Stocks and Shares ISA
SIPP
$0.72
(4.28%)$0.72
(4.28%)Company Information
About this company
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Key people
Key facts
- EPICCNTA
- LocationUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS1523091007
- Market cap$2.25bn
- Employees77
- Shares in issue0.00
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.